Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Market Cap	113.38B
Revenue (ttm)	1.64B
Net Income (ttm)	-791.34M
Shares Out	233.19M
EPS (ttm)	-3.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,135,300
Average Volume	731,567
Open	500.00
Previous Close	508.00
Day's Range	478.20 - 510.00
52-Week Range	152.00 - 541.50
Beta	0.78
RSI	49.05
Earnings Date	Nov 18, 2025

About HKG:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally. Its product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC ta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1,837
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6990

Financial Performance

In 2024, HKG:6990's revenue was 1.93 billion, an increase of 25.48% compared to the previous year's 1.54 billion. Losses were -266.77 million, -48.92% less than in 2023.

Financial numbers in CNY